AI pharmaceutical-development unicorn Deep Intelligent Pharma has recently completed a new financing round of US$60 mill ...

In this Pharma Matters Q&A, Anshul Gupte of PCI Pharma Services discusses investments and opportunities in sterile ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR® AI platform, today announced the expansion of predictBBB.ai into a ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Phase 3 trials for chronic weight management planned for initiation in the second half of 2026 Petrelintide demonstrated ...

In part 2 of a multi-part series, David Schoneker, president, Black Diamond Regulatory Consulting, explains what drives the ...

Royalty Pharma plc has completed a transaction to monetize remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in cash, resulting in total proceeds of $530 million ...

Lantern has successfully confirmed PTGR1 as a key biomarker that it intends to use to optimize patient selection based on potential tumor sensitivity to the drug candidate LP-184. LP-184 is a ...

In Detroit, they say that we don’t have healthcare in our country, we have sick care. Under the Trump Administration, our ...